标准或减量达比加群与利伐沙班在非瓣膜性房颤中的比较有效性与安全性
本研究基于法国医疗数据库,对非瓣膜性房颤新用药者比较标准剂量或减量达比加群与利伐沙班的有效性和安全性,按性别、年龄、首次配药日期和高维倾向评分匹配,随访2年。标准剂量组(每组8290例)达比加群对比利伐沙班:卒中或系统性栓塞(SSE)HR 0.92(95%CI 0.67-1.26),大出血(MB)HR 0.59(95%CI 0.39-0.90),死亡HR 0.84(95%CI 0.65-1.11);减量组(每组7639例)SSE HR 0.73(95%CI 0.59-0.94),MB HR 0.74(95%CI 0.57-0.96),死亡HR 0.95(95%CI 0.83-1.09)。结论:无论标准剂量或减量,达比加群有效性相似或优于利伐沙班,且出血风险更低,死亡率无差异。
要点
- 标准剂量达比加群较利伐沙班大出血风险更低(HR 0.59,95%CI 0.39-0.90)。
- 减量达比加群较利伐沙班SSE风险更低(HR 0.73,95%CI 0.59-0.94)。
- 两种剂量下达比加群与利伐沙班的死亡风险均无显著差异。
核心结论
- 在非瓣膜性房颤患者中,标准或减量达比加群的有效性相似或优于利伐沙班,且大出血风险更低,死亡风险无差异。
研究设计与样本
- 法国医疗数据库新用药者研究,标准剂量和减量达比加群或利伐沙班,按性别、年龄、首次配药日期和高维倾向评分匹配,随访2年。
- 标准剂量组每组8290例,平均年龄67岁;减量组每组7639例,平均年龄80岁。
主要发现
- 标准剂量组达比加群对比利伐沙班:SSE HR 0.92(95%CI 0.67-1.26),MB HR 0.59(95%CI 0.39-0.90),死亡HR 0.84(95%CI 0.65-1.11)。
- 减量组达比加群对比利伐沙班:SSE HR 0.73(95%CI 0.59-0.94),MB HR 0.74(95%CI 0.57-0.96),死亡HR 0.95(95%CI 0.83-1.09)。
临床怎么用
- 对于非瓣膜性房颤患者,选择达比加群(标准或减量)可能较利伐沙班降低大出血风险,减量时还可能降低卒中或系统性栓塞风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dabigatran and rivaroxaban at standard or reduced doses have been compared to warfarin in nonvalvular atrial fibrillation (NVAF), but not to each other. This was a new user study of standard dose and reduced dose dabigatran or rivaroxaban for NVAF in the French healthcare database, matched on gender, age, date of first dispensing, and high-dimensional propensity score, followed 2 years. Hazard ratios (HRs; 95% confidence intervals (CI)) of stroke or systemic embolism (SSE), major bleeding (MB), or death were computed. In matched standard-dose patients (8,290 per arm), mean age 67 years, HRs for dabigatran vs. rivaroxaban were SSE 0.92 (95% CI = 0.67-1.26), MB 0.59 (95% CI = 0.39-0.90), and death 0.84 (95% CI = 0.65-1.11). In reduced-dose patients (7,639 per arm), mean age 80 years, HRs for dabigatran vs. rivaroxaban were SSE 0.73 (95% CI = 0.59-0.94), MB 0.74 (95% CI = 0.57-0.96), and death 0.95 (95% CI = 0.83-1.09). In conclusion, at either dose, dabigatran had similar or better effectiveness than rivaroxaban but lower bleeding risk. Death rates were not different.
引用
- Blin P, Dureau-Pournin C, Cottin Y, et al. Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation. Clin Pharmacol Ther. 2019. PMID: 30499605. doi:10.1002/cpt.1318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。